Creation of an international Inter-Society Pediatric Allergology Network (ISPAN): preliminary data from a survey of pediatric allergist in Italy, Spain, and Portugal
Main Article Content
Keywords
allergen immunotherapy, allergic diseases, allergy network, Mediterranean area, pediatric allergists
Abstract
Allergic rhinitis and asthma are among the most important chronic diseases in children and young adults, with increasing prevalence and significant impact on the healthcare system and quality of life. Allergen Immunotherapy (AIT) remains the only causal treatment capable of modifying the natural course of allergy. However, despite its proven efficacy, real-world data on its application in the pediatric population remain limited. This study aimed to evaluate and compare the management and clinical practice of allergic diseases in the pediatric population, particularly the current use of AIT for respiratory allergy, by pediatricians and allergists in Italy, Spain, and Portugal. A comprehensive online survey developed by the pediatric allergy societies of the three countries was distributed to pediatric allergists to collect demographic data, diagnostic and treatment approaches, and AIT prescription attitudes. A total of 171 responses were analyzed in this study. The results show that most allergists treat high numbers of pediatric allergic patients on weekly basis, primarily using skin and laboratory tests for diagnosis of allergy, and pulmonary function tests to diagnose asthma. AIT was prescribed by the majority of allergists (91.2%), primarily for children aged ≥5 years, and mainly for allergic rhinoconjunctivitis and asthma. Of the respondents, 64.1% chose sublingual AIT over subcutaneous AIT (35.9%) because of compliance (77.6%) or practical reasons (67.9%). Patients were mainly treated for 3 years (39.7%) to 5 years (21.2%) and were regularly monitored every 6 months (51.3%). This initiative marks the first multinational collaboration between pediatric national allergology societies in Mediterranean countries, establishing a fundamental network for future collaborations. This study provides valuable insights and encourages further efforts to harmonize pediatric allergy care across similar sociocultural and environmental regions.
References
2 Licari A, Ciprandi G, Marseglia GL, Silvestri M, Tosca MA, Anastasio E, et al. Asthma in children and adolescents: The ControL’Asma project. Acta Biomed. 2020 Sep 15;91(11-S):e2020002. 10.23750/abm.v91i11-S.102953.
3 Global Initiative for Asthma (GINA). Relatório Principal GINA 2024 - Iniciativa Global para a Asma – GINA [Internet]. [cited 2024]. 263 p. Available from: https://ginasthma.org/2024-report/
4 Mims, JW. Asthma: Definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5(Suppl:1):S2–6. 10.1002/alr.21609
5 Tosca MA, Marseglia GL, Ciprandi G, ControL’Asma Study Group. The real-world “ControL’Asma” study: a nationwide taskforce on asthma control in children and adolescents. Allergol Immunopathol (Madr). 2021;49(1):32–3. 10.15586/aei.v49i1.14
6 Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG, et al. 2019 ARIA care pathways for allergen immunotherapy. Allergy Eur J Allergy Clin Immunol. 2019;74(11):2087–102. 10.1111/all.13805
7 Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy Eur J Allergy Clin Immunol. 2017;72(11):1597–631. 10.1111/all.13201
8 Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, et al. EAACI guidelines on allergen immunotherapy: House dust mite-driven allergic asthma. Allergy Eur J Allergy Clin Immunol. 2019;74(5):855–73. 10.1111/all.13749
9 Alvaro-Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, Arasi S, et al. EAACI allergen immunotherapy user’s guide. Pediatr Allergy Immunol. 2020;31(S25):1–101. 10.1111/pai.13189.
10 Muraro A, Roberts G. Allergen immunotherapy guidelines – Part 2 recommendations. EAACI [Internet]. [cited 2017]. 190 p. Available from: https://medialibrary.eaaci.org/mediatheque/media.aspx?mediaId=60223&channel=8518
11 Bartra J, García-Moral A, Enrique E. Geographical differences in food allergies. Bundesgesundheitsbl. 2016;59(6):755–63. 10.1007/s00103-016-2357-0. (in English)
12 Li S, Wu W, Wang G, Zhang X, Guo Q, Wang B, et al. Association between exposure to air pollution and risk of allergic rhinitis: A systematic review and meta-analysis. Env Res. 2022;1(205):112472. 10.1016/j.envres.2021.112472
13 Song M, Hwang S, Son E, Yeo HJ, Cho WH, Kim TW, et al. Geographical differences in the risk of asthma and allergic rhinitis according to urban/rural areas: A systematic review and meta-analysis of cohort studies. J Urban Heal. 2023;100(3):478–92.
14 Catamerò F, Barbaglia S, Heffler E, Giovannini M, Paoletti G. Patients’ perspective on allergen immunotherapy for respiratory allergy. Curr Opin Allergy Clin Immunol. 2025 Aug 25. Epub ahead of print. 10.1097/ACI.0000000000001110
15 Novembre E, Giovannini M, Barni S, Mori F. From the global initiative for asthma report and asthma guidelines to real-life asthma control: is there room for improvement? Ital J Pediatr. 2022 Jul 5;48(1):110. 10.1186/s13052-022-01304-8
16 Giovannini M, Catamerò F, Agache I, Bognanni A, Canonica GW, Del Giacco S, et al. Real-world evidence in pediatrics. Pediatr Allergy Immunol. 2025 Sep;36(9):e70183. 10.1111/pai.70183
17 Buta F, Paoletti G, Bragato MC, Giovannini M, Canonica GW, Heffler E. Real-world evidence of allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2024 Dec 1;24(6):529–35. 10.1097/ACI.0000000000001026
18 Sousa-Pinto B, Valiulis A, Melén E, Koppelman GH, Papadopoulos NG, Makela M, et al. Asthma and rhinitis control in adolescents and young adults: A real-world MASK-air study. Pediatr Allergy Immunol. 2024 Feb;35(2):e14080. 10.1111/pai.14080